Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)
Historic Interest Coverage Ratio for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2022 value amounting to 928119.2.
- Inhibikase Therapeutics' Interest Coverage Ratio fell 41696255.1% to 928119.2 in Q1 2022 from the same period last year, while for Dec 2022 it was 3625721.6, marking a year-over-year decrease of 48909522.26%. This contributed to the annual value of 741.16 for FY2021, which is 67316.52% down from last year.
- According to the latest figures from Q1 2022, Inhibikase Therapeutics' Interest Coverage Ratio is 928119.2, which was down 41696255.1% from 31907.98 recorded in Q4 2021.
- In the past 5 years, Inhibikase Therapeutics' Interest Coverage Ratio registered a high of 52.08 during Q2 2020, and its lowest value of 928119.2 during Q1 2022.
- In the last 3 years, Inhibikase Therapeutics' Interest Coverage Ratio had a median value of 222.54 in 2021 and averaged 109939.28.
- In the last 5 years, Inhibikase Therapeutics' Interest Coverage Ratio crashed by 20598.01% in 2021 and then plummeted by 41696255.1% in 2022.
- Quarter analysis of 3 years shows Inhibikase Therapeutics' Interest Coverage Ratio stood at 168.21 in 2020, then crashed by 18869.2% to 31907.98 in 2021, then tumbled by 2808.74% to 928119.2 in 2022.
- Its last three reported values are 928119.2 in Q1 2022, 31907.98 for Q4 2021, and 28477.96 during Q3 2021.